Cyclosporine Therapy for Acquired Factor VIII Inhibitor in a Patient with Systemic Lupus Erythematosus

Summary

The case of a 27-year-old woman with systemic lupus erythematosus and development of an autoantibody against factor VIII during an exacerbation of her underlying disorder is described. Attempts to eliminate the antibody with high dose gammaglobulin and repeated courses of cyclophosphamide failed, whereafter she received cyclosporine in increasing doses. When therapeutic serum levels of cyclosporine were achieved (150-350 ng/ml) the inhibitor rapidly decreased and disappeared with a concomitant normalization of the factor VIII levels. Treatment with cyclosporine was subsequently reduced and discontinued after one year, and at present no inhibitor is detectable. In view of the successful results with cyclosporine treatment in 4 of 6 previous cases and in all 3 previous cases with autoimmune disorders, this regimen should be evaluated in a systematic manner as a potential first line drug in patients with acquired hemophilia and an underlying autoimmune disorder.

• References

• 1 Green D, Lechner K. A survey of 215 non-hemofilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-203
• 2 Spero JA, Lewis JH, Hasiba U. Corticosteroid therapy for acquired F VIII:C inhibitors. Br J Haematol 1981; 48: 635-642
• 3 Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765-768
• 4 Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with F VIII autoantibodies. Thromb Haemost 1993; 70: 753-757
• 5 Lian EC-Y, Larcada AF, Chiu AY-Z. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110: 774-778
• 6 Rhodes EGH, Boesen EAM, Corringham RET, Matthews KB, Tuddenham EGD, Kemoff PBA. Disappearance of antibodies to factor VIII in a patient with acquired haemophilia and carcinoma of the pancreas during cytotoxic therapy with fluorouracil and CCNU. Thromb Haemost 1984; 52: 131-133
• 7 Schwerdtfeger R, Hintz G, Huhn D. Successful treatment of a patient with postpartum factor VIII inhibitor with recombinant human interferon a 2a. Am J Hematol 1991; 37: 190-193
• 8 Hess AD, Colombani PM. Mechanism of action. In: Cyclosporini Progress in Allergy Borel JF. (ed) Karger, Basel: 1986. 38 185-193
• 9 Van Buren C. Cyclosporine: progress, problems, and perspectives. Surg Clin North Am 1986; 66: 435-449
• 10 Borel JF, von Graffenried B. Sandimmun® (Cyclosporin A) and autoimmunity. In: Recent advances in systemic lupus erythematosus Lamber PH, Perrin L, Izui S. (eds) Academic Press; New York: 1983: 313-318
• 11 Pijnappels MI, Briet E, van der Zwet G, Huisden R, van Tilburg NH, Euederink F. Evaluation of the cuticle bleeding time in canine haemophilia A. Thromb Haemost 1986; 55: 70-73
• 12 Bach JF, Feutren G. Contrasting effects of ciclosporin on humoral and cell-mediated immunity in patients with autoimmune diseases. In: Ciclosporin in autoimmune diseases Schindler R. (ed) Springer-Verlag; Berlin: 1985: 33-38
• 13 Hart HC, Kraijenhagen RJ, Kerckhaert JAM, Verdel G, Freen M, van de Wiel A. A patient with a spontaneous factor VIII:C autoantibody: Successful treatment with cyclosporine. Transplant Proc 1988; 20 (Suppl. 04) 323-328
• 14 Pflieger G, Boda Z, Harsfalvi J, Flora-Nagy M, Sari G, Pecze K, Rak K. Cyclosporin treatment of a woman with acquired haemophilia due to factor VIII:C inhibitor. Postgrad Med J 1989; 65: 400-402
• 15 McLeod BC, McKenna R, Chediak J. Treatment of acquired factor VIII inhibitors with antibody removal by apheresis followed by immunosuppression with prednisone and cyclosporin. Blood 1989; 74 (Suppl) 393a (abstract)
• 16 Siegbahn A, Feltelius N, Norlen BJ, Hedner U. Treatment of acquired hemophilia due to F VIII:C autoantibodies with recombinant F Vila and cyclosporine. Thromb Haemost 1995; 73: 1424 (abstract)